Western Michigan University

ScholarWorks at WMU
Master's Theses

Graduate College

4-1996

The Effects of Chromium Picolinate Supplementation on Body
Fat, Lean Body Mass, and Respiratory Exchange Ratio
Matthew K. Beaty

Follow this and additional works at: https://scholarworks.wmich.edu/masters_theses
Part of the Health and Physical Education Commons

Recommended Citation
Beaty, Matthew K., "The Effects of Chromium Picolinate Supplementation on Body Fat, Lean Body Mass,
and Respiratory Exchange Ratio" (1996). Master's Theses. 4494.
https://scholarworks.wmich.edu/masters_theses/4494

This Masters Thesis-Open Access is brought to you for
free and open access by the Graduate College at
ScholarWorks at WMU. It has been accepted for inclusion
in Master's Theses by an authorized administrator of
ScholarWorks at WMU. For more information, please
contact wmu-scholarworks@wmich.edu.

THE EFFECTS OF CHROMIUM PICOLINATE SUPPLEMENTATION
ON BODY FAT, LEAN BODY MASS, AND
RESPIRATORY EXCHANGE RATIO

by
Matthew K. Beaty

A Thesis
Submitted to the
Faculty of The Graduate College
in partial fulfillment of the
requirements for the
Degree of Master of Arts
Department of Health, Physical Education,
and Recreation

Western Michigan University
Kalamazoo, Michigan
April 1996

ACKNOWLEDGMENTS
Sincere appreciation is extended to the members of my advisory committee, Dr.
Roger Zabik, Dr. Mary Dawson, and Dr. Patricia Frye. Thank you for your efforts and
guidance when I had no direction, keeping me sane during data collection, and the
countless times you read, re-read, and edited my thesis.
I would like to acknowledge David Paschke for his assistance in obtaining the
chromium and supplies required during data collection. I am most indebted to the subjects
who consented to be studied and the volunteers who helped test them. I would also like
to thank my mentor, Dr. David Martin, my exercise physiology professor at the University
of Wyoming, for sharing his wisdom and passion in the field of exercise physiology with
me.
Finally, thanks to my parents and family for their love, support, and understanding.
Thank you, Mom and Dad, for encouraging me to do my best, but most of all for
encouraging me to be myself.
Matthew K. Beaty

11

THE EFFECTS OF CHROMIUM PICOLINATE SUPPLEMENTATION
ON BODY FAT, LEAN BODY MASS, AND
RESPIRATORY EXCHANGE RATIO
Matthew K. Beaty, M.A.
Western Michigan University, 1996
The purpose of this study was to investigate the effects, on college-age males, of
ingesting chromium picolinate over a 6-week period when administered as a supplement
to their diet. Fifty males, ages 18 to 25 years, had their respiratory exchange ratio (R),
body fat percentage, and lean body mass measured prior to and following a 6-week
supplementation period. Subjects were randomly placed into a chromium, placebo, or
control group. All subjects were instructed to maintain daily activities. Analysis of
variance revealed no significant differences in R values, body fat percentage, or lean body
mass among the chromium, placebo, or control groups. These findings showed that
chromium picolinate supplementation did not significantly influence the metabolism of
college-age males over a 6-week period.
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CHAPTER I
INTRODUCTION
Dietary supplementation is becoming more common in today's society, and there
are many conflicting opinions concerning which supplements should be taken. The
recommended dosage for chromium is 50 to 200 µg daily as established by the National
Academy of Sciences. It was found that approximately 90% of American diets were
below the lowest recommended levels (Anderson & Kozlovsky, 1985). Diets designed by
22 United States Department of Agriculture (USDA) nutritionists averaged only 15 µg
per 1,000 calories (Anderson, 1992). Modem food processing techniques add to this
problem by removing up to 800/4 of the chromium in most cereals, grains, and sugars (Pi
Sunyer & Offenbacher, 1984). In addition, consumption of high-sugar diets increases
chromium excretion by 10% to 300% (Kozlovsky, Moser, Reiser, & Anderson, 1986).
Chromium picolinate has been reported to increase muscle and reduce fat in
athletes as well as in sedentary individuals. Chromium is an essential insulin cofactor. A
deficiency in chromium affects the insulin sensitivity of the cells, which in tum slows the
burning of food for energy. If the food we consume is not being used for fuel, the body
then converts it to fat.
Insulin works in an anabolic manner on the essential amino acids used in building
muscle tissue. Once inside the cell, the amino acids are assembled to repair the exercised
1

2

muscle.
Statement of the Problem
The problem of the study was to investigate the effects, on college age males (ages
18 to 25 years), of ingesting chromium picolinate over a 6-week period when
administered as a supplement to their diet. Respiratory exchange ratio (R) (at a
submaximal state), body fat percentage, and lean body mass were measured to determine
whether a shift in substrate utiliz.ation, reduction in percentage of body fat, or an increase
in lean body mass occurred over the 6-week period.
Significance of the Study
Chromium picolinate is currently being used by a wide variety of individuals from
diabetics to body builders to help regulate blood sugar, reduce body fat, increase muscle
mass, and provide a variety of other outcomes. If both the reductions in body fat and
increases in lean body mass attributed to chromium supplementation occur, then substrate
utilization can be more accurately pin-pointed as the cause for these effects. Because
chromium picolinate has been on the market as a supplement for less than a decade, much
of the research to date has been on its effects, rather than on why these effects occur. This
study could provide support for the premise that chromium supplementation changes
substrate utilization.
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Delimitations
The study was delimited to the following:
1. Subjects were male college students, aged 18 to 25 years (N = 50).
2. Subjects were free from any blood glucose regulatory problems or diseases,
such as hypoglycemia or diabetes.
3. Subjects were randomly assigned to one of three groups as follows: (1)
chromium supplementation group, (2) placebo group, and (3) control group.
4. Subjects continued their daily activities as usual, including aerobic and
anaerobic training or lack thereof.
5. Body composition and R levels were measured before and after a 6-week
supplementation period.
6. Body composition was measured by hydrostatic weighing.
7. R levels were measured using a Quinton metabolic cart with subjects in a fasted
state.
8. Subjects walked on the treadmill until R levels reached a steady state.
Limitations
The study was limited by the following:
1. Daily activities of subjects were not controlled.
2. The investigator was unable to personally conduct all of the hydrostatic and R
testing both before and after supplementation.
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3. The investigator could not control whether the subjects maintained their normal
diet during the supplementation period.
4. The investigator could not control whether the subjects were taking other
supplements that could produce the same or opposite effects.
5. Chromium levels could differ with each subject prior to supplementation.
6. Supplementation of 200 µg of chromium picolinate could affect each subject
differently.
Assumptions
The study was conducted under the following assumptions:
1. Subjects' diet and exercise levels were maintained.
2. Subjects took the supplement or placebo on a daily basis.
3. Instruments calibrated according to manufacturer recommendations produced
accurate results.
Research Hypotheses
The researcher hypothesized that:
1. The supplementation group experienced a greater reduction in the R level than
the placebo group or the control group.
2. The supplementation group experienced a greater reduction in body fat
percentage than the placebo group or the control group.
3. The supplementation group experienced a greater increase in lean body mass
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than the placebo group or the control group.
4. The placebo group experienced a greater reduction in the R level than the
control group.
5. The placebo group experienced a greater reduction in body fat percentage than
the control group.
6. The placebo group experienced a greater increase in lean body mass than the
control group.
Definition of Terms
For consistency of interpretation, the following terms were defined:
1. Anabolism. Energy-requiring, building phase of metabolism in which simpler
substances are combined to form more complex substances (Marieb, 1992).
2. Glucagon. A hormone, produced by the Islets of Langerhans of the pancreas,
that elevates the level of blood sugar (Rhoades & Pflanzer, 1992).
3. Glucose. A simple sugar that is transported via the blood and metabolized by
tissues (Powers & Howley, 1994).
4. Glycerol. A sugar alcohol; a building block of fats (Marieb, 1992).
5. Glycogen. A polymer of glucose; the form in which glucose is stored in the
body, mainly in muscles and the liver (Fox, Bowers, & Foss, 1989).
6. Hypoglycemia. A decrease in the blood glucose concentration to below normal
levels (Rhoades & Pflanzer, 1992).
7. Lipase. An enzyme responsible for the breakdown of triglycerides to free fatty
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acids and glycerol (Powers & Howley, 1994).
8. Lipolysis. The breakdown of triglycerides in adipose tissue to free fatty acids
and glycerol for subsequent transport to tissues for metabolism (Powers & Howley,
1994).
9. Respiratory exchange ratio (R). The ratio of CO2 production to 02
consumption. R values are indicative of substrate utilization during steady state exercise;
a value of 1. 0 represents 100% carbohydrate metabolism, and 0. 7 represents 100% fat
metabolism (Powers & Howley, 1994).
10. Somatomedin. A growth factor found in many tissues, including the liver, that
mediates the effect of growth hormone on cartilage (Rhoades & Pflanzer, 1992).

CHAPTER II
REVIEW OF LITERATURE
History
Development
In 1969, Mertz postulated that the physiological effects of chromium were
mediated by an organic chromium complex, glucose tolerance factor (GTF), which was
produced in the body, but also absorbed efficiently from certain foods such as brewer's
yeast (McCarty, 1991). Researchers in the past 25 years have failed to confirm the
structure of, or verify the existence of, a GTF produced by the body as suggested by
Mertz. A crystalline preparation of GTF has never been achieved, and presently there is
no convincing evidence that the body makes a specific organic chromium complex that
mediates chromium's actions. Over a decade ago, USDA scientists under the direction of
Dr. Gary Evans developed chromium tripicolinate, now known as "chromium picolinate,"
as an organic nutritional source of chromium (U.S. Patent# 4,315,927). Chromium
picolinate is more biologically active than inorganic forms of chromium and is presumed
to have effects on the body similar to the GTF proposed by Mertz.
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Chemical Make-up
Chromium picolinate is the transport form of chromium. It is stable, electrically
neutral, and lipophilic. In this form, chromium is complexed with three molecules of
picolinic acid, which is produced naturally in the human liver and kidney as an amino acid
metabolite. However, if this form proves too stable, it might well limit bioactivity;
presumably the release of the free chromic ion is required for bioactivity (McCarty, 1991).
Chromium picolinate was patented in 1988 by the United States Government and licensed
exclusively to the Nutrition 21 company based in San Diego, CA (U.S. Patent #
4,315,927).
Safety
Dosage
The "safe and adequate" intake of dietary chromium as established by the National
Research Council and recommended by the 1989 Recommended Dietary Allowances
(RDA) handbook is 50 to 200 µg per day. The average daily intake of chromium among
adult Americans is approximately 30 µg, which suggests that chromium supplementation
could be beneficial (Anderson & Kozlovsky, 1985). Further research is needed to
determine if doses higher than the current 200 µg will have a greater effect. The
recommended intake of 50 to 200 µg is based·on sedentary individuals and not on active
individuals or athletes. Individuals with weights greater than 165 lb may require 400 to
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600 µg per day to meet their needs (Colgan, 1993).
The toxicity of chromium is about 1 mg per 100 g of body weight in humans
(National Research Council [U.S.] Food Protection Committee, 1973). At this level it
would require a 154-lb person to ingest 700,000 µg or 3,500 to 14,000 times the 50 to
200 µg safe and effective range recommended in the·RDA. In another study conducted
by Dr. Gary Evans, the toxic level of chromium picolinate was estimated to be in excess
of2.2 g/kg ofbody weight. This would be 100,000 times greater than the recommended
nutritional intake for that same 154-lb person (Evans, 1989b).
Chromium Loss With Exercise
Exercise has been shown repeatedly to increase insulin metabolism, which in tum
increases the body's chromium requirement (Colgan, 1993). In a study done by Campbell
and Anderson (1987), urinary loss of chromium increased almost five-fold after a 6-mile
run, and overall daily loss of chromium was twice as much on running days as on non
running days.
Side Effects
Chromium picolinate has been available to the American consumer since 1988 as
a nutritional supplement. Reports of suspected side effects have been negligible despite
the fact that millions ofconsumers are now using it as a daily supplement (Evans, 1993).
One potential concern is that diabetics who respond well to chromium picolinate may
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experience hypoglycemic episodes if they fail to adjust their medications appropriately
(Evans, 1989a). It is highly recommended that people with diabetes or hypoglycemia use
chromium picolinate only under a doctor's supervision.
Insulin Metabolism
Description
Insulin allows cells to take in glucose in response to an increase in blood sugar
levels. It also regulates the use and storage of glucose, carbohydrate, protein, and fat
within the body and keeps the body in homeostasis when these are involved. After protein
is digested into its constituent amino acids, insulin facilitates entry of these amino acid
building blocks into muscle cells. Once inside the cell, they are built into muscle proteins,
again under the influence of insulin (Riales, 1979).
Insulin Sensitivity
Chromium helps cells, particularly skeletal muscle, bind insulin, which increases
the efficiency of the active insulin in the body. "Unless you have diabetes, you have all the
insulin you need, because your body can make it instantly. To take extra insulin would be
highly toxic to the non-diabetic Colgan, 1993, p. 314). Because chromium picolinate
11 (

has been extremely effective in potentiating insulin action in humans and is lipophilic, it
is suspected that as a complex, chromium may actually exert its influence in the plasma
membrane of the cell (Evans & Bowman, 1992).
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Evans and Bowman (1992) suggested that the number of insulin receptors on cells
grown in the presence of chromium picolinate is greater than the number of insulin
receptors on cells grown without chromium picolinate present. Thus, the increased
efficiency and sensitivity to insulin may be due to an increased number of binding sites on
the cells. "The effects of exercise on insulin sensitivity are regional, with increased
sensitivity confined to the previously exercised muscle groups, combined with decreased
insulin sensitivity in the non-exercised muscles" (Devlin, 1992, p. 1693).
Blood Glucose Levels
By increasing the rate of insulin internalization into the cells, the body can adapt
to change more quickly and efficiently by maintaining blood glucose levels with a
minimum output of insulin by the pancreas. In a controlled study at Mercy Hospital, San
Diego, CA, Press, Geller, and Evans (1990) found that, in diabetics, chromium picolinate
reduced the fasting blood sugar by 18% and significantly improved blood sugar stability.
Fasting blood sugar levels were reduced by 35% over an 8-week period in a study of
American Chippewa Indians with non-insulin dependent diabetes mellitus (Evans, 1991).
Body Composition
"The supplemental use of chromium picolinate helps maintain and even build
additional muscle, while fat is burned for energy" (Challem, 1994, p. 29). Although people
who exercise benefit the most from chromium picolinate, sedentary individuals benefit as
well. Kaats, Fisher, and Blum (1991) found that overweight people taking 200 µg of
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chromium picolinate lost an average of3. 0 lb in body fat and gained 1. 5 lb in muscle after
2 months. It was noted by Evans (1989a) and Press et al. (1990) that the effects of
chromium picolinate could be measured after only 6 weeks of supplementation. Those
taking 400 µg ofchromium picolinate lost an average of 4. 6 lb in fat and gained 1. 0 lb in
muscle.
Recent studies have been prompted by the knowledge that insulin has an anabolic
effect on skeletal muscle and other tissues, promoting amino acid uptake and protein
synthesis and retarding protein degradation (McCarty, 1991). It can be reasoned that
good chromium nutrition might potentiate this anabolic effect by promoting greater
insulin activity. Initial studies suggested that supplemental chromium picolinate in
exercising young adults tended to promote the development oflean body mass and muscle
bulk (McCarty, 1991).
Insulin also had a direct anabolic effect in promoting the manufacture of
somatomedins by the liver (Draznin & SWomo, 1989). Somatomedins mediated the effect
of human growth hormone as well as increased ribonucleic acid (RNA) and
deoxyribonucleic acid (DNA) synthesis thus acting as a growth factor. Without
somatomedins, very little muscle growth occurred (Rudman, 1985).

Substrate Utilization
Changes With Exercise
"Proteins play only a minor role as a substrate during exercise, with fat and
carbohydrate serving as the major sources of energy during activity in the healthy
individual consuming a balanced diet" (Powers & Howley, 1994, p. 58). During moderate
physical exercise, both decreases in insulin secretion �d increases in glucagon secretion
have been found to play important roles in the prevention of hypoglycemia. These changes
in insulin and glucagon, as well as the increased metabolism of skeletal muscle during
exercise, cause a shift in substrate utilization.
Endurance Exercise
During the transition from rest to submaximal exercise almost all of the energy is
derived from glycogen stored in the active muscles. During the subsequent 20 min of
exercise, liver and muscle glycogen provide about 40% to 500/4 of the energy requirement,
with the remaining energy coming from fat breakdown. As exercise continues and
glycogen stores become reduced, however, an increasingly greater percentage of energy
is supplied through fat metabolism (McArdle, Katch, & Katch, 1991).
Blood glucose is transported into the cell more rapidly in the presence of
chromium picolinate by making the cell membrane more permeable. Chromium picolinate
also increases the effectiveness of lipase, which is responsible for the breakdown of
triglycerides to fatty acids and glycerol, and thus increases fat metabolism during
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submaximal exercise (Powers & Howley, 1994). These two factors coupled together
allow the body to increase the rate of fat metabolism through an increased efficiency of
carbohydrate metabolism during exercise.
Resistance Exercise
Resistance exercise, which is usually in the form of short bouts of maximal
exertion, predominantly requires the use of blood glucose and muscle glycogen stores for
fuel. Because of the short duration of bouts of resistance exercise, the body does not rely
as much on fat as a fuel source as in aerobic exercise, because there is enough time
between bouts to replace glycogen stores in the muscle. In bouts lasting approximately
60 s the body obtains about 70% of the energy from carbohydrates and the remaining
30% from fats (Powers & Howley, 1994). Shorter bouts of exercise obviously use a
greater percentage of carbohydrate as a fuel source.
Respiratory Exchange Ratio
R, the ratio of CO2 production to 02 consumption, indicates which substrate is
primarily being used by the body for fuel. An R value of 1. 00 represents 100%
carbohydrate metabolism, and an R value of 0.70 represents 100% fat metabolism
(Powers & Howley, 1994). The measured values in individuals usually lie somewhere
between these two values and rarely indicate that someone is burning only one substrate
at any given time.

CHAPTER III
DESIGN AND METHODOLOGY
The purpose of the study was to investigate the.effects, on college age males (ages
18 to 25 years), of ingesting chromium picolinate over a 6 week period when
administered as a supplement to their diet. Respiratory exchange ratio (R) (at a
submaximal state), body fat percentage, and lean body mass were measured to determine
whether a shift in substrate utilization, reduction in percentage of body fat, or an increase
in lean body mass occurred over the 6-week period. The study included the following
procedural steps: (a) selection of subjects, (b) instrumentation, (c) testing procedures, (d)
design of study, and (e) treatment of data.
Selection of Subjects
All of the subjects were volunteers who were enrolled at Western Michigan
University during the course of the investigation. The characteristics of the subjects
included the following: (a) males; (b) ages 18 to 25 years; (c) individuals without known
blood glucose regulatory problems; such as hypoglycemia or diabetes; and (d) individuals
who had given their informed consent. Appendix A contains the Human Subjects
Institutional Review Board's letter of approval. Appendix B contains a copy of the
consent form each subject signed before participation in the study. Appendix C contains
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a copy of the screening form used to eliminate subjects with known blood glucose
regulatory problems. Appendix D contains the data recording form used to record subject
data throughout the study.
Instrumentation
The instruments used for gathering the data were selected based on availability
and reliability. The hydrostatic tank and weighing instrumentation in the laboratory at
Western Michigan University were used. The hydrostatic weighing was done using a
water tank with dimensions of 4 ft by 4 ft by 4 ft. Underwater weights were measured
using an Omega Engineering CCA - 215 load cell integrated with an Omega DP40 series
indicator. The analog-to-digital conversion was accomplished with a Zenith 386/20
computer on locally produced software. Body weight was measured using a physician's
scale. R values were measured using the Quinton Q-plex 1 metabolic cart. Subjects
walked on a Quinton (model 18-60) treadmill. Subjects' vital capacities were measured
using a Micro Medical Limited microspirometer. Chromium picolinate was obtained from
NOW Foods, based in Glendale Heights, IL.
Testing Procedures
Initial Procedure
All testing was completed in the Exercise Physiology Lab in the University
Recreation Center, at Western Michigan University, Kalamazoo. Prior to the study, a
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consent fonn was signed and dated by each of the subjects. Within the consent fonn, the
testing procedure and possible risks of the study were explained. Subjects were asked to
wear clothing and footwear that were functional and appropriate for walking on the
treadmill as well as bring a swimsuit for having their body composition measured in the
hydrostatic tank. Subjects were allowed time to become comfortable with the treadmill
and metabolic cart before the testing process began. The supplementation, placebo, and
control groups maintained their current activity levels and nutrition schedule for the
following 6-week period. After the 6-week period, R value, body fat percentage, and lean
body mass were calculated again using the same protocol.
Body Weight
Body weight was measured using a Health-O-Meter balance scale (Continental,
Chicago, IL). The subject was instructed to wear clothing that could be worn in the
hydrostatic tank. The subject was instructed to stand erect and still on the scale while the
measurement was taken (Lohman, Roche, & Martorell, 1988).
Respiratory Exchange Ratio
R values were measured using the Quinton metabolic cart. The subjects were
instructed to walk on a Quinton treadmill at a speed of 3. 5 mph. R values were taken at
20-s intervals for 3 min after a steady state was achieved. Baseline R values were obtained
by calculating the mean R value of two trials, one from each of 2 different days.
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Hydrostatic Weighing
After obtaining an R value on the 2nd day, each subject had his percentage of
body fat and lean body mass determined using hydrostatic weighing. Hydrostatic weighing
is considered the gold standard for validating all other methods of measuring body
composition. The hydrostatic weighing procedure estimates the body fat percentages at
an accuracy level of± 2.5% of the true value (Lohman, 1981). Hydrostatic weighing uses
Archimedes' principle. When submerged, body muscle and bone sink due to densities
higher than that of water (Kreighbaum & Barthels, 1990).
Residual volume (RV) was estimated using the formula of RV= 0.24 x VC for
males. Vital capacity was measured using a Micro Medical Limited microspirometer.
Body mass was measured in water and in air. The hydrostatic weighing was done in a 64
cubic foot tank with an observation window. The weighing was done until the subject had
three trials within 1% of each other or a maximum of 10 trials, talcing either the mean of
the last 3 trials or the mean of the 3 trials within 1%. Body density was calculated using
the formula recommended by Powers and Howley (1994). The Siri equation for percent
body fat was used to calculate body fat percentages (Powers & Howley, 1994). The
formula, lean body mass = body mass - fat mass, was used to calculate lean body mass
(McArdle et al., 1991).
Design of Study
The subjects were randomly assigned to either the chromium picolinate
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supplementation group, the placebo group, or the control group by someone not directly
involved in the study. The random assignments were sequestered until all data were
collected. The study was double blind in that neither the subjects nor the investigator was
aware of which subjects received the supplement and which received the placebo. All
groups participated in the pretest in the week prior to the treatment. Based on the results
of previous studies, a 6-week supplementation period was selected. After the 6-week
treatment period, the posttest was administered in the same manner as the pretest. Both
the pretest and the posttest were administered by the investigator and/or other graduate'
students at Western Michigan University who had been instructed and trained by the
investigator.
Treatment of Data
A split-plot factorial analysis of variance (ANOVA) was used to determine if
significant differences in R value, body fat percentages, and lean body mass occurred
among the chromium picolinate group, the placebo group, and the control group. Pretest
and posttest trials were compared to determine the effect of chromium picolinate
supplementation. The 2V program from the BMDP statistical package was used to
calculate the ANOVAs.

CHAPTER IV
RESULTS AND DISCUSSION·
In this study the researcher investigated the ·effects of 6 weeks of chromium
picolinate supplementation on R value, body fat percentage, and lean body mass. Results
were discussed under the following subheadings: (a) Independent Variables, (b) Subject
Demographics, (c) Respiratory Exchange Ratio, (d) Body Fat Percentage, and (e) Lean
Body Mass. A split-plot factorial ANOVA design was used to analyze the dependent
variables R, body fat percentage, and lean body mass. The independent variables in the
design were the repeated measure, pretest and posttest, and the treatment groups,
chromium picolinate, placebo, and control. All hypotheses were tested statistically at the
. 05 level ofsignificance.
Results
Independent Variables
Subjects were randomly assigned to either the chromium picolinate
supplementation group, the placebo group, or the control group. The chromium picolinate
group ingested 1. 6 mg ofchromium picolinate each day for 6 weeks, which contained 200
µg ofchromium. The placebo group ingested 1.6 mg oflactose each day for 6 weeks, and
the control group received nothing. All groups participated in the pretest in the week
20
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prior to treatment. The subjects were placed in the treatment groups by the research
advisor, making the study double blind, so that neither the subjects nor the investigator
was aware of which subjects received the supplement and which received the placebo.
Subject Demographics
The average ages for the subjects in the chromium picolinate supplementation,
placebo, and control groups were 20.1 years, 20.9 years, and 19.9 years, respectively.
Although the study began with 60 subjects, 20 in each group, the number of subjects
completing the study were 15, 19, and 16 in the picolinate supplementation, placebo, and
control groups, respectively. The initial mean R values for the chromium picolinate,
placebo, and control groups were 0.83, 0.85, and 0.82, respectively. The initial body fat
percentage means were 13.84%, 16.91%, and 13.57% for the chromium picolinate,
placebo, and control groups, respectively. The initial lean body mass means were 142.13
lb, 142.82 lb, and 141.87 lb for the chromium picolinate, placebo, and control groups,
respectively.
Respiratory Exchange Ratio
Means and standard deviations for R for the chromium picolinate, placebo, and
control groups are displayed in Table 1. The mean R values, 0.83 and 0.82, did not
change from the beginning to the end of the 6-week period for the chromium picolinate
supplementation and control groups, respectively. The mean R value decreased from 0.85
to 0.84 for the placebo group. The standard deviations (SD) were fairly constant for all
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groups from pretest to posttest. The SD for R was lower at the end of the 6-week period,
0.03, than prior to treatment, 0.05, in the chromium picolinate group. The SD for the
placebo and control groups changed from 0.04 and 0.05 to 0.05 and 0.03, respectively
for the pretest and posttest.
Table 1
Means and Standard Deviations of Respiratory Exchange Ratio
Treatment
Chromium
Picolinate
M

Trial

Control

Placebo
M

M

Pretest

0.83

0.05

0.85

0.04

0.82

0.05

Posttest

0.83

0.03

0.84

0.05

0.82

0.03

A split-plot factorial ANOVA design was used to analyze the dependent variable,
R. The ANOVA summary table for R is presented in Table 2. The analysis of variance
revealed no significant differences among the chromium picolinate, placebo, and control
groups in the dependent variable, R, .E(2, 47) = 2.62, 12 > .05. There was no significant
differences between trials, .E(l, 47) = 0.10, 12 > .05. There was no significant interaction
effect between treatments and trials, .E(2, 47) = 0.08, 12 > .05.
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Table 2
Analysis of Variance Summary Table for Respiratory Exchange Ratio

E

Source
Between Subjects
Treatment (TR)

0.01230

2

0.00615

Subjects w/ groups

0.11031

'47

0.00235

Trials (T)

0.00008

1

0.00008

0.10

TRxT

0.00014

2

0.00007

0.08

T x Subj w/ groups

0.03964

47

0.00084

2.62

Within Subjects

Body Fat Percentage
Means and standard deviations for body fat percentages for the chromium
picolinate, placebo, and control groups are displayed in Table 3. The mean body fat
percentage for the chromium picolinate supplementation group decreased from 13.84%
to 13. 69% over the 6-week period. The body fat percentag� increased in the placebo
group from 16.91% to 17.32% and decreased in the control group from 13.57% to
13 .49% during the 6-week period. The SD decreased for all three groups. The SD
dropped to 5.96 from 6.04, to 6.18 from 7.04, and to 5.72 from 6.07 for the chromium,
placebo, and control groups, respectively.
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Table 3
Means and Standard Deviations of Body Fat Percentage
Treatment

Chromium
Picolinate
Trial

M

Control

Placebo
M

M

Pretest

13.84

6.04

16.91

7.04

13.57

6.07

Posttest

13.69

5.96

17.32

6.18

13.49

5.72

A split-plot factorial ANOVA design was also used to analyze the dependent
variable, body fat percentage. The ANOVA summary table for body fat percentage is
presented in Table 4. The analysis of variance revealed no significant differences among
the treatments, (chromium picolinate, placebo, and, control group) for body fat
percentage, E(2, 47) = 1.88, p_ > .05. There was no significant difference between trials,
E(l, 47) = 0.06, p_ > .05. There was no significant interaction effect between treatments
and trials, E(2, 47) = 0.54, p_ > .05.
Lean Body Mass
Means and standard deviations for lean body mass for the chromium picolinate,
placebo, and control groups are displayed in Table 5. The mean lean body mass for the
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Table 4
Analysis of Variance Summary Table for Body Fat Percentage

E

Source
Between Subjects
283.92761

2

141.96381

3558.38095

47

75.71023

Trials (T)

0.08681

1

0.08681

0.06

TRxT

1.63947

2

0.81973

0.54

71.03554

47

1.51139

Treatment (TR)
Subjects w/ groups

1.88

Within Subjects

T x Subj w/ groups

chromium picolinate, placebo, and control groups increased over the 6-week period from
142.13 lb to 142.79 lb, 142.82 lb to 143.78 lb, and 141.87 lb to 142.83 lb, respectively.
The SD decreased from 15.25 to 14.84 in the chromium picolinate group. SDs for the
placebo and control groups increased from 17.08 and 11.44 to 17.67 and 12.76,
respectively.
A split-plot factorial ANOV A design was also used to analyze the dependent
variable, lean body mass. The ANOVA summary table for lean body mass is presented in
Table 6. The analysis of variance revealed no significant differences among the chromium
picolinate, placebo, and control groups in lean body mass, E(2, 47) = 0.02, p > .05. There
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was no significant difference between, E(l, 47) = 3.60, R > .05. There was no significant
interaction effect between treatments and trials, E.(2, 47) = 0.05, R > .05.
Table 5
Means and Standard Deviations of Lean Body Mass in Pounds
Treatment

Chromium
Picolinate
M

Trial

Control

Placebo
M

M ·

Pretest

142.13

15.25

142.82

17.08

141.87

11.44

Posttest

142.79

14.84

143.78

17.67

142.83

12.76

Discussion
Based on the results of this study, there were no significant differences among the
chromium picolinate, placebo, and control groups in regard to the R value, body fat
percentage, or lean body mass. Similarly there were no significant differences between the
trials and no significant interaction effects.
Although it was not statistically significant, there were small differences among
groups for the R value. The differences were not expected. If chromium picolinate
enabled the body to bum more fat, it should have resulted in a lower R value after the 6-
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week supplementation period. The opposite results were found. R values increased
slightly for the chromium group, but decreased for the other groups.
Table 6
Analysis of Variance SummaryTable for Lean Body Mass
Source
Between Subjects
Treatment (TR)
Subjects w/ groups

0.02

19.28794

2

9.64397

21380.10074

47

454.89576

18.27935

1

18.27935

3.60

0.46235

2

0.23117

0.05

238.91040

47

5.08320

Within Subjects
Trials (T)
TR xT
T x Subj w/ groups

There was a slight gain in lean body mass within all groups over the 6-week
period. As can be seen inTable 5, all three groups experienced a small increase in lean
body mass. This may have occurred as a result of a learning effect associated with the
hydrostatic weighing procedure. Also, although subjects were instructed not to do so,
some subjects may have increased their workouts or weight training programs over the
6-week period.
The only other difference worth noting was the body fat percentage among
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groups. As can be seen in Table 3, the mean body fat percentage decreased slightly for
the chromium group and increased slightly for the placebo group.
The results of this investigation were not in agreement with the findings of Evans
(1989a) or Hasten, Rome, Franks, and Hegsted (1992). Both studies included a chromium
picolinate supplementation group and a placebo group, but neither included a control
group.
Evans (1989a) reported the results for two separate studies that found significant
decreases in body fat percentages a� well as significant increases in lean body mass in
college-age males after 6 weeks of resistance training in combination with 200 µg per day
of chromium picolinate supplementation. The sample size of his first study was quite
small, N = 10. Also, anthropometric measurements and skinfold measurements were used
to determine body composition. Predictions based on skinfold measurements are generally
less accurate than predictions based on hydrostatic weighing when used to estimate body
fat percentage and lean body mass. Although Evans (1989a) reported, "In both of our
studies, the young men who ingested a daily supplement of chromium picolinate showed
an increase in lean body mass and a decrease in body fat" (p. 174), he indicated in his first
study that, "the body weight of the men who consumed chromium picolinate increased
significantly by 2.2 kg and there was a slight but not significant increase in percent fat"
(p. 170). These statements appear to be in conflict. The lack of tables in the article may
have contributed to this confusion or misinterpretation of data. In the second
investigation, Evans (1989a) reported a 2.7% decrease in percentage body fat and a 1.8
kg increase in lean body mass after only 14 days. Again, if hydrostatic weighing had been
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used instead of skinfold measurements, these results may have been different.
Hasten et al. (1992) found significant differences over a 12-week period between
the pretest and posttest for body weight, sum of three circumferences, and sum of three
skinfolds. Methodological limitations in this experiment may have accounted for the
positive results. Anthropometric measurements were used to estimate changes in body
composition rather than hydrostatic weighing.
The present investigation agreed with the findings of more recent studies done by
Clancy et al. (1994) and Hallmark et al. (1996). They studied the effects of chromium
supplementation, 200 µg in the form of 1. 6 mg chromium picolinate, and resistive exercise
training on body composition, muscle strength, and urinary chromium loss. Both studies
concluded that no significant differences in body composition accompanied the dietary
supplementation of chromium picolinate. Clancy et al. used the sum of seven skinfolds as
well as hydrostatic weighing to determine body composition for 3 8 football players and
found no significant differences over 9 weeks. Similarly, Hallmark et al. used the sum of
6 skinfolds as well as hydrostatic weighing to determine body composition. Likewise,
there were no significant changes in body composition or lean body mass over a 12-week
period.

CHAPTER V
SUMMARY, FINDINGS, CONCLUSIONS, AND RECOMMENDATIONS
The purpose ofthis study was to determine the effect of6 weeks of chromium
picolinate supplementation on the R value, body fat percentage, and lean body mass. The
research was discussed under the following headings: (a) Summary, (b) Findings, (c)
Conclusions, and (d) Recommendations.
Summary
The purpose ofthe study was to investigate the effects, on college age males (ages
18 to 25 years), of ingesting chromium picolinate over a 6 week period when
administered as a supplement to their diet. Respiratory exchange ratio (R) (at a
submaximal state), body fat percentage, and lean body mass were measured to determine
whether a shift in substrate utilization, reduction in percentage ofbody fat, or an increase
in lean body mass occurred over the 6-week period. The 50 male subjects investigated
were randomly placed into 3 groups: (1) chromium picolinate group, n = 15; (2) placebo
group, n = 19; and (3) control group, n = 16. All subjects were instructed to maintain
daily activities.
R values were measured using the Quinton Q-plex 1 metabolic cart. The subjects
were instructed to walk on a Quinton (model 18-60) treadmill at a speed of3.5 mph. R
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values were taken at 20-s intervals for 3 min after a steady state was achieved. Body fat
and lean body mass were measured using hydrostatic weighing. The hydrostatic weighing
was done using a water tank with dimensions of 4 ft by 4 ft by 4 ft. Underwater weights
were measured using an Omega Engineering CCA - 215 load cell integrated with an
Omega DP40 series indicator. The analog-to-digital conversion was accomplished with
a Zenith 386/20 computer on locally produced software. The hydrostatic weights were
taken until the subject had 3 trials within I% of each other or a maximum of IO trials,
taking either the mean of the last 3 trials or the mean of the 3 trials within I%.
Three split-plot factorial ANOVAs were calculated by computer using the
following dependent variables: (a) R, (b) body fat percentage, and (c) lean body mass. The
independent variables in the design were the repeated measure, pretest and posttest, and
the treatment groups, chromium picolinate, placebo, and control. All hypotheses were
tested statistically at the .05 level of significance.
Findings
None of the research hypotheses were supported. The analysis of variance
revealed no significant differences among the chromium picolinate, placebo, and control
groups for the dependent variable, R, E(2, 47) = 2.62, n > .05. There was no significant
difference between trials, E( l , 47) = 0.10, n > .05. There was no significant interaction
effect between treatments and trials, E(2, 47) = 0.08, n > .05. The analysis of variance
revealed no significant differences among the chromium picolinate, placebo, and control
groups for body fat percentage, E(2, 47) = 1.88,

n > .05. There was no significant
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difference between trials, E( l , 47) = 0.06, 12 > .05. There was no significant interaction
effect between treatments and trials, E(2, 47) = 0.54, 12 > .05. The analysis of variance
revealed no significant differences among the chromium picolinate, placebo, and control
groups for lean body mass, E(2, 47) = 0.02, 12 < .05. There was no significant difference
between trials, E.(1, 47) = 3.60, 12 > .05. There was no significant interaction effect
between treatments and trials, E.(2, 47) = 0.05, 12 > .05.
Conclusions
Based on the results of this study, it appeared that 6 weeks of dietary
supplementation of 200 µg of chromium picolinate by sedentary males, aged 18 to 25
years, does not significantly affect R value, body fat percentage, or lean body mass.
Recommendations
Further research is warranted to confirm the present findings and to examine the
effects of chromium picolinate supplementation over a longer supplementation period
and at higher doses. Further testing should be done to explore the use of chromium
picolinate by women as well as men. Several suggestions to improve the testing of a
fasting R value are: (a) control the subjects' meal the night prior to testing, (b) test all
subjects in the morning after a night of fasting, (c) have the subjects walk longer on the
treadmill, and (d) have the subjects walk at a slower speed.

Appendix A
Human Subjects Institutional Review Board Approval,
Western Michigan University
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Human Subjects Institutional Review 8oa.-d

Kala"nazoo, Michigan 49008-3899
616 387-8293
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WESTERN MICHIGAN UNIVERSl1Y

Date:

October 4, 1995

To:

Matthew Beaty

(\

\,.Iii� Cl

From: Richard Wright, Chair\._))
Re:

HSIRB Project Number 95-09-02

This letter will serve as confirmation that your research project entitled "The effects of chromium
picolinate supplementation on body fat, lean body mass and respiratory exchange ratio" has been
approved under the f ull category of review by the Human Subjects Institutional Review Board.
The conditions and duration of this approval are specified in the Policies of Western Michigan
University. You may now begin to implement the research as described in the application.
Please note that you must seek specific approval for any changes in this design. You must also
seek reapproval if the project extends beyond the termination date. In addition if there are any
unanticipated adverse reactions or unanticipated events associated with the conduct of this research,
you should immediately suspend the project and contact the Chair of the HSIRB for consultation.
The Board wishes you success in the pursuit of your research goals.
Approval Termination:
xc:

October 4, 1996

Roger Zabik, HPER.
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Western Michigan University
Department of Health, Physical Education, and Recreation
Principal Investigator : Dr. Roger Zabik
Research Associate : Matthew K. Beaty
I have been invited to participate in an experimental research project entitled "The
Effects of Chromium Picolinate Supplementation on Body Fat, Lean Body Mass, and
Respiratory Exchange Ratio. I understand that this research is intended to determine if
the dietary supplementation of 200 µg of chromium, in the form of chromium picolinate,
will affect the body fat, lean body mass, or respiratory exchange ratio of an individual.
I further understand that this project is Matt Beaty's master's thesis in the department of
Health, Physical Education & Recreation at Western Michigan University.
11

Chromium, like iron or zinc, is an essential mineral in _the human diet. Chromium is an
essential insulin cofactor. A deficiency in chromium affects the insulin sensitivity of the
cells, which in tum slows the burning of food for energy. If the food we consume isn't
being used for fuel, the body then converts it to fat. There are no known side effects to
the ingestion of 200 µg of chromium and the toxic levels have been found to be, at the
minimum, 3,500 times the dose being given.
My agreement to participate indicates that I will attend four 45-min to I-hour individual
sessions. Two of these sessions will take place prior to the 6-week supplementation
period, and two will take place after the 6-week period. These sessions will take place
in the Exercise Physiology Laboratory in the University Recreation Center, Gary Wing.
These sessions will involve walking on a treadmill at 3. 5 mph (a fast walking pace), while
breathing into a mouthpiece for about 10 minutes to determine respiratory exchange ratio.
The 3. 5 mph rate is approximately the same pace at which most students walk to classes.
In addition, the second and fourth sessions will involve the determination of body fat and
lean body mass by hydrostatic weighing. Hydrostatic weighing will include my being
submerged in water tank that is a 4' x 4' x 4' tank with a glass side or viewing window.
There will be three groups, two that receive a capsule (supplement or placebo) that will
be taken daily. One group receives chromium picolinate, and one group gets a natural
dietary supplement that does not include chromium picolinate. The third group (control)
will receive no supplement. If I am placed into one of the two groups that receives
capsules, I agree to take the supplement as directed. I agree that I will not pull the
capsule apart, it is important to keep the capsule intact as one of the substances used in
the research can be an irritant to the skin.
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As in all research, there may be unforeseen risks to the participant. If an accidental injury
occurs, appropriate emergency measures will be taken; however, no compensation or
treatment will be made available to me except as otherwise stated in this consent form.
I am aware that there may be some risk of injury, such as muscle soreness or possible
heart attack. However, appropriate measures will be taken to minimize these risks. The
investigators and others assisting in the data collection are all CPR and First Aid trained.
Emergency response procedures are also posted in the Exercise Physiology lab where all
testing will take place. I also understand that I may terminate my involvement with this
research for any reason at anytime without affecting my academic evaluations in any way.
I may benefit from my participation by knowing my percentage of body fat and lean body
mass. I may also gain insight as to the substrate that I am burning at low intensity
activities such as walking at 3. 5 mph. I may also gain knowledge as to the importance of
minerals in my diet.
I am aware that all information and data pertaining to my participation is confidential. My
name will only appear on my data recording form and no individual names will be printed
on any paper or reports other than this form, which will be seen only by the investigator
and those helping to test. All data will be retained for a period of 3 years in a locked file
controlled by the principal investigator. At the conclusion of the study there will be a
short individual debriefing meeting in which all subjects who received an supplement will
be informed as to which group (supplementation or placebo) they were assigned to.
If I have any questions or concerns about this study I may contact Matt Beaty at 3872689 or Dr. Zabik at 387-2713. I may also contact the chair of the Human Subjects
Institutional Review Board (387-8293) or the Vice President for Research at 387-5926.
I affirm that I am between the ages of 18 and 25 years old and free of any known blood
glucose regulatory problem such as hypoglycemia or diabetes. My signature below
indicates that I understand the purpose and requirements of the study and that I agree to
participate.

Signature

Date

Appendix C
Subject Screening Form
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Subject Screening Form
1. Do you have any known blood glucose regulatory disease such as diabetes or
hypoglycemia?
(Y / N)
2. Are you allergic to any food substances?
3. If you answered yes to question #2, please list the food allergies that you have.

An answer of yes to item 1 will result in the subjects elimination from the study. Anyone
indicating a food allergy to milk or dairy products will be placed in a group other than the
placebo group by the principal investigator.

AppendixD
Data Recording Form
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DATA RECORDING FORM
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Subject's Name_____________ Date____
Age__ Phone Number-------

Initial
R VALUES
1.
Day 1
6.
1.
Day2
6.

2.
7.
2.
7.

3.-- 4.-- 5.-8.__ 9.__ DailyMean__
5.-3. --4.
8. -- 9. --- DailyMean-GrandMean ---HYDROSTATIC WEIGHING
Vital Capacity(VC) l. ___ 2. ___ 3. ___
Water Temperature __ °C
Air Temperature __ °C
Body Weight
Tare Weight ____
Trial l.__ 2.
3.__ 4.__ 5.-10.-8.
6.__ 7.
9.
%BF----

Post Supplementation
R VALUES
1.
Day3
6.
1.
Day4
6.

LBM

3.-- 4.-- 5. -8.-- 9.__ DailyMean__
5.-3.-- 4.
8. -- 9.-- DailyMean-GrandMean ---HYDROSTATIC WEIGHING
Vital Capacity(VC) l.___ 2.___ 3. ___
Water Temperature __ °C
Air Temperature __ °C
Tare Weight ____
Body Weight
Trial l.__ 2.
3.__ 4. __ 5. -6.__ 7.
8.__ 9.__ 10.-%BF---2.
7.
2.
7.

LBM----
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